SCHEMBL5773842

SCHEMBL5773842

N#Cc1ccc(CCNC(=O)C[C@H]2Nc3ccccc3NC2=O)cc1

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 18/20 0.77
ALDH1A1 P00352 16/20 0.77
TAAR1 Q96RJ0 1/20 0.77
HSD17B10 Q99714 13/20 0.70
MAPT P10636 9/20 0.70
HPGD P15428 7/20 0.70
POLB P06746 3/20 0.70
MAPK1 P28482 2/20 0.70
MEN1 O00255 5/20 0.64
KMT2A Q03164 5/20 0.64
HTT P42858 3/20 0.64
ALOX15 P16050 6/20 0.57
GAA P10253 5/20 0.56
RAB9A P51151 2/20 0.53
TSHR P16473 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.48
NTSR1 P30989 1/20 0.48
NPC1 O15118 1/20 0.47
TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4428703 0.87 KDM4E (1.00) KDM4EALDH1A1TAAR1HSD17B10MAPT
SCHEMBL6404552 0.87 ALDH1A1 (0.58) KDM4EALDH1A1TAAR1HSD17B10MAPT
SCHEMBL2874464 0.83 ALDH1A1 (0.53) KDM4EALDH1A1TAAR1HSD17B10MAPT
SCHEMBL13598876 0.83 KDM4E (0.82) KDM4EALDH1A1TAAR1HSD17B10MAPT
SCHEMBL4417733 0.83 KDM4E (0.82) KDM4EALDH1A1TAAR1HSD17B10MAPT
SCHEMBL2874135 0.81 ALDH1A1 (0.54) KDM4EALDH1A1TAAR1HSD17B10MAPT
SCHEMBL6701145 0.75 KDM4E (0.77) KDM4EALDH1A1TAAR1HSD17B10MAPT
SCHEMBL4418592 0.75 KDM4E (0.77) KDM4EALDH1A1TAAR1HSD17B10MAPT
SCHEMBL2869386 0.74 ALDH1A1 (0.67) KDM4EALDH1A1TAAR1HSD17B10MAPT
SCHEMBL2870661 0.74 ALDH1A1 (0.67) KDM4EALDH1A1TAAR1HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1572209-A4 NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS MERCK & CO INC (US) 2006-12-06 EP disclosed
EP-1572209-A1 NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS Merck & Co., Inc. (US) 2005-09-14 EP disclosed
US-6908921-B2 Quinoxalinone derivatives as bradykinin B1 antagonists MERCK & CO., INC. (US) 2005-06-21 US disclosed
US-20050020591-A1 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds SU DAI-SHI (US) 2005-01-27 US disclosed
US-20040132733-A1 Novel quinoxalinone derivatives as bradykinin B1 antagonists MERCK & CO., INC. 2004-07-08 US disclosed
WO-2004054584-A1 NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS MERCK & CO., INC. (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020591-A1 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds BDKRB1, BDKRB2, LTB4R2 KDM4E 3049/4885ALDH1A1 3743/4885TAAR1 568/4885
US-20040132733-A1 Novel quinoxalinone derivatives as bradykinin B1 antagonists BDKRB1, BDKRB2, LTB4R2 KDM4E 3438/4885ALDH1A1 3321/4885TAAR1 506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.